

27th October 2020


NIFTY TO TRADE BETWEEN 11,850-11,650.

On daily scale Nifty has formed strong bearish candle after trading in range for week it failed to sustain above support of 11,800 levels. Index is holding the support of 20 EMA which lays around 11,730 levels. Index below 11,700 levels it will continue to move towards 11,600 levels.

TRADERS COMMENT

Indian benchmark share indices closed in the red on Monday led by losses in metals and auto stocks. An elusive US stimulus deal kept sentiment muted in the region. Nifty ended lower by 162.60 points or 1.36% at 11,767.80 level and Sensex ended lower by 540 points or 1.33% at 40145.50.

Hindalco Power Grid Hero Motocorp Maruti Suzuki India Bharti Infratel BHEL RIL Kotak Mahindra Bank Bajaj Auto L&T Gail NTPC Ambuja Cements HDFC Axis Bank Adani Ports SBI Indusind Bank ACC Bhalti Airtel -6.8% -3.4% 0.0% 3.4% 6.8%






E-mail : research@Dealmoney.in www.dealmoneyonline.com


Chart of the Day COALINDIA FUT Sell below Rs 114.

The stock is trading below to its prior low and below to its 20 ema support. We recommend sell only below Rs114 with the stoploss of Rs116 for the target of Rs110.






)5-07T03:4**202002**05-29T03:4**202002**06-19T03:4**202002**07-10T03:4**202002**07-31T03:4**202002**08-21T03:4**202002**09-11T03:4**202002**10-05T03:4**202002**10-26T03:45:0



Technical call of the Day HDFCLIFE Buy above Rs 579.

We recommend a Buy in the stock only above Rs579 with the stoploss of Rs568 for the target of Rs600.



STOCKS TRADING IN POSITIVE ZONE: KOTAKBANK, NESTLEIND. STOCKS TRADING IN NEGATIVE ZONE: HEROMOTOCO, BAJAJAUTO.

• Aurobindo Pharma: It has signed definitive agreement to sell Natrol, a unit of Aurobindo Pharma USA, Inc, to an affiliate of New Mountain Capital to combine with Jarrow Formulas. The all-cash transaction is valued at \$550 million (around Rs 4,048 crore). Subject to customary closing conditions and regulatory approvals, the transaction is expected to close by January 2021.

CMP: 784.7
P/E(ttm): 20.4
Impact Positive

• Sterlite Technologies: Sterlite Technologies has decided to fast track its planned augmentation of optical fibre cable capacity, buoyed by the order book and demand funnel, as it looks to undertake expansion in two phases, possibly at lower costs. The company has decided to lift the 'pause and hold' on expansion to move full throttle ahead. The capacity is expected to rise from 18 million fibre km (FKm) to 24 million Fkm in the first phase by the end of December. In the second phase, the company plans to move from 24 million Fkm to 33 million Fkm by March or April next year.

CMP: 152.6
P/E(ttm): 29.3
Impact Positive

• Polycab India: The company has reported 10.37% rise in its net profit of Rs 212.09 crore for the quarter under review as against net profit of Rs 192.16 crore for the same quarter in the previous year. However, total income of the company decreased 5.67% at Rs 2124.99 crore for Q2FY21 as compared Rs 2252.60 crore for the corresponding quarter previous year.

CMP: 957.1
P/E(ttm): 22.4
Impact Positive

Alembic Pharmaceuticals: Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Timoptic-XE Ophthalmic Gel Forming Solution, 0.25% and 0.5%, of Bausch Health US, LLC.

CMP: 960.4 P/E(ttm): 15.6 Impact Positive

Tech Mahindra: The company has reported a fall of 31.14% in its net profit at Rs 961.50 crore for the quarter under review as compared to Rs 1,396.30 crore for the same quarter in the previous year. Total income of the company decreased by 1.51% at Rs 7,561.40 crore for Q2FY21 as compared Rs 7,677.10 crore for the corresponding quarter previous year.


CMP: 819.3
P/E(ttm): 19.2
Impact Neutral

ttm = trailing twelve months

Economic Snapshot

- In a big relief to borrowers, the Finance Ministry has approved guidelines for a scheme for grant of ex-gratia payment of the difference between compound interest and simple interest for six months of loans up to Rs 2 crore. The guidelines came after the Supreme Court directed the Centre to implement as soon as possible interest waiver on loans of up to Rs 2 crore under the RBI moratorium scheme in view of the COVID-19 pandemic. As per the guidelines, the scheme can be availed by borrowers in specified loan accounts for a period from March 1 to August 31, 2020. Housing loan, education loans, credit card dues, auto loans, MSME loans, consumer durable loans and consumption loans are covered under the scheme.
- Government think tank Niti Aayog member (health) V K Paul has said the aayog is looking at many reform ideas in the health sector, including aligning traditional and modern approaches for a 'larger good'. He said the government is committed to strengthening the traditional system of medicine (homoeopathy and Ayurveda) as well as the modern system of medicine (allopathy). He also said 'It makes eminent logic that the best of traditional medicine and best of modern medicine therapies be brought together for a larger good of people and there are ways of practicing integrated medicine'. Paul pointed out that it has already happened to an extent, as yoga is now part of practice in several conditions like in hypertension. He noted that 'There is a scope to align these approaches for the larger benefit of society... as a think tank, we are looking at many reform ideas in the health sector, aligning traditional and modern approaches for a larger good'. Integrative medicine is an approach that combines modern medicine with alternative systems like Ayurveda and yoga.

Explore Our Products



FREQUENCY	ALLOCATION	DURATION	RISK
4 calls a Day	Average Daily Premium of Rs.50,000	Intraday	High Risk


SALIENT FEATURES:


- Fixed time for call generation 2 calls at 9:30am and 2 calls @ 12:00pm
- High Risk High Returns product
- Focused product for Intraday Derivative Traders
- Daily 4 calls to gain from intraday momentum
- High beta Midcap and Large cap F&O stocks for better entry and exit.

Dealmoney

DERIVATIVES

Open Interes				
Stock	Open Interest (contracts)	Ol Change (%)	Price (Rs.)	Price change (%)
MINDTREE	684,000	738.2%	1376.65	0.1%
MFSL	655,200	581.1%	577.65	-2.1%
BERGEPAINT	976,800	346.2%	597.00	-2.5%
FEDERALBNK	33,337,000	338.7%	54.40	-3.3%
VOLTAS	953,000	300.4%	691.20	-2.2%







Top 5 Traded	l Stock Futures	S		
Stock	Expiry Date	No of contracts traded	Contract value (Rs. Lacs)	LTP
RELIANCE	29-Oct-20	48,609	505,691	2035
RELIANCE	26-Nov-20	22,139	231,005	2042
KOTAKBANK	29-Oct-20	41,226	228,482	1414
ICICIBANK	29-Oct-20	39,543	222,706	405
HDFC	29-Oct-20	31,327	194,432	2073

Top 5 Trad						
Stock	Expiry Date	Option Type	Strike price	No of contracts traded	Contract value (Rs. Lacs)	LTP
RELIANCE	29-Oct-20	CE	2,100	26,978	288,125	8.80
RELIANCE	29-Oct-20	PE	2,000	24,104	244,646	13.10
RELIANCE	29-Oct-20	CE	2,200	13,273	147,701	2.70
RELIANCE	29-Oct-20	CE	2,120	12,310	132,453	6.20
KOTAKBANK	29-Oct-20	CE	1,400	22,266	126,502	31.25

Top 5 Contra	ct Future Vol	umes		
Stock	Expiry Date	No of Contracts traded	Current Cash Volume	Cash Delivery %
RELIANCE	29-Oct-20	48,609	6,324,776	3672.0%
KOTAKBANK	29-Oct-20	41,226	1,941,895	2421.0%
ICICIBANK	29-Oct-20	39,543	7,444,536	3429.0%
HDFC	29-Oct-20	31,327	2,856,064	5796.0%
AXISBANK	29-Oct-20	27,306	5,346,359	3064.0%

Stock	Expiry Date	No of Contracts traded	Current Cash Volume	Cash Delivery %
IDEA	29-Oct-20	81	31,834,676	3444.0%
NATIONALUM	29-Oct-20	373	3,813,247	4714.0%
BHEL	29-Oct-20	376	7,503,878	2504.0%
ESCORTS	29-Oct-20	538	288,160	2229.0%
TORNTPOWER	29-Oct-20	616	114,852	2459.0%

Bottom 5 Contract Future Volumes

NOTE: OI Gainers are for 26-Nov-2020 expiry; while OI Losers are for 29-Oct-2020 expiry.

Company Name	Closing Price	S3	S2	S1	Pivot	R1	R2	R3
ACC	1578.80	1532.20	1547.73	1563.27	1589.03	1604.57	1645.87	1687.17
Adani Ports	363.70	346.80	352.43	358.07	365.98	371.62	385.17	398.72
Ambuja Cements	245.05	235.90	238.95	242.00	245.50	248.55	255.10	261.65
Asian Paints	2080.45	2023.75	2042.65	2061.55	2088.95	2107.85	2154.15	2200.45
Aurobindo Pharma	784.70	730.40	748.50	766.60	790.55	808.65	850.70	892.75
Axis Bank	493.35	471.95	479.08	486.22	498.03	505.17	524.12	543.07
Bajaj Auto	2895.15	2656.25	2735.88	2815.52	2964.63	3044.27	3273.02	3501.77
Bank Of Baroda	42.70	41.35	41.80	42.25	43.00	43.45	44.65	45.85
Bharti Airtel	434.05	416.55	422.38	428.22	433.83	439.67	451.12	462.57
Bharti Infratel	188.35	177.65	181.22	184.78	189.17	192.73	200.68	208.63
BHEL	29.45	28.05	28.52	28.98	29.62	30.08	31.18	32.28
Bosch	11841.35	11185.25	11403.95	11622.65	11951.25	12169.95	12717.25	13264.55
BPCL	346.10	331.40	336.30	341.20	347.45	352.35	363.50	374.65
Cipla	747.15	720.85	729.62	738.38	751.07	759.83	781.28	802.73
Coal India	114.55	110.50	111.85	113.20	115.55	116.90	120.60	124.30
Dr. Reddy'S Lab	4978.10	4840.50	4886.37	4932.23	4997.12	5042.98	5153.73	5264.48
Eicher Motors	2108.10	1967.65	2014.47	2061.28	2137.97	2184.78	2308.28	2431.78
Gail	85.50	82.20	83.30	84.40	86.10	87.20	90.00	92.80
Grasim	780.00	746.15	757.43	768.72	779.28	790.57	812.42	834.27
HCL Technologies	847.80	823.20	831.40	839.60	850.25	858.45	877.30	896.15
HDFC	2073.35	2021.55	2038.82	2056.08	2070.02	2087.28	2118.48	2149.68
HDFC Bank	1210.90	1167.20	1181.77	1196.33	1219.17	1233.73	1271.13	1308.53
Hero Motocorp	2897.95	2630.00	2719.32	2808.63	2964.32	3053.63	3298.63	3543.63
Hindalco	172.40	156.30	161.67	167.03	174.97	180.33	193.63	206.93
HUL	2166.75	2112.60	2130.65	2148.70	2160.35	2178.40	2208.10	2237.80
ICICI Bank	404.45	383.75	390.65	397.55	408.35	415.25	432.95	450.65
ldea	8.90	8.55	8.67	8.78	8.97	9.08	9.38	9.68
Indusind Bank	616.65	593.80	601.42	609.03	621.17	628.78	648.53	668.28
Infosys	1112.45	1076.70	1088.62	1100.53	1115.07	1126.98	1153.43	1179.88
пс	168.55	164.90	166.12	167.33	169.47	170.68	174.03	177.38
Kotak Mahindra Bank	1416.90	1265.70	1316.10	1366.50	1397.75	1448.15	1529.80	1611.45
L&T	951.75	926.75	935.08	943.42	951.33	959.67	975.92	992.17
Lupin	962.90	917.25	932.47	947.68	972.67	987.88	1028.08	1068.28
M&M	597.15	563.35	574.62	585.88	605.87	617.13	648.38	679.63
Maruti Suzuki India	7054.80	6708.80	6824.13	6939.47	7050.38	7165.72	7391.97	7618.22
NTPC	85.95	80.60	82.38	84.17	86.08	87.87	91.57	95.27
ONGC	68.20	65.80	66.60	67.40	68.45	69.25	71.10	72.95
Pow er Grid	172.05	166.35	168.25	170.15	171.55	173.45	176.75	180.05
RIL	2029.10	1935.05	1966.40	1997.75	2049.85	2081.20	2164.65	2248.10
SBI	196.70	187.20	190.37	193.53	198.77	201.93	210.33	218.73
Sun Pharma	474.50	454.80	461.37	467.93	477.67	484.23	500.53	516.83
Tata Motors	133.70	121.70	125.70	129.70	135.25	139.25	148.80	158.35
Tata Motors DVR	55.50	51.40	52.77	54.13	56.57	57.93	61.73	65.53
Tata Pow er	53.90	50.20	51.43	52.67	54.18	55.42	58.17	60.92
Tata Steel	408.40	384.95	392.77	400.58	411.97	419.78	438.98	458.18
TCS	2688.20	2631.05	2650.10	2669.15	2689.55	2708.60	2748.05	2787.50
Tech Mahindra	819.25	773.30	788.62	803.93	829.32	844.63	885.33	926.03
Ultratech	4485.40	4374.30	4411.33	4448.37	4496.38	4533.42	4618.47	4703.52
Wipro	339.80	328.50	332.27	336.03	340.47	344.23	352.43	360.63
Yes Bank	13.15	11.85	12.28	12.72	13.33	13.77	14.82	15.87
Zee Entertainment	176.70	165.05	168.93	172.82	179.88	183.77	194.72	205.67

Disclaimer

For private circulation only Website: www.dealmoneyonline.in
DISCLAIMER: SEBI Research Analyst Registration No: INH000002319For any grievance mail at compliance@dealmoney.in

Dealmoney Securities Private Limited (hereinafter referred to as "Dealmoney") is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and MCX Stock Exchange Limited. Dealmoney is also registered as a Depository Participant with CDSL. Dealmoney is in the process of making an application with SEBI for registering it as a Research Entity in terms of SEBI (Research Analyst) Regulations, 2014. Dealmoney or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing/dealing in securities Market and no material disciplinary action has been taken by SEBI/other regulatory authorities impacting Dealmoney's Equity Research Analysis. Dealmoney or its associates/ analyst including its relatives do not hold any actual/beneficial ownership of more than 1% in the company/ies covered by Analyst (hereinafter referred to as "Subject Company/ies"). Dealmoney or its associates/analyst including its relatives may hold financial interest in the company/ies covered by Analyst (hereinafter referred to as "Subject Company/ies"). Dealmoney or its associates/analysts or his/her relative does not receive any compensation or other benefits from the subject company/ies mentioned in this research report (hereinafter referred to as "Report") or from a third publication of the Report. Accordingly, Dealmoney or its associates/analyst or his/her relative does not have any other material conflict of interest at the time of publication of the Report.

Research analyst/s engaged in preparation of the Report, has not received any compensation / managed or co-managed public offering of securities of the subject company/ies / has not received compensation for investment banking or merchant banking or brokerage services from the subject company/ies / has not received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company/ies / has not received compensation or other benefits from the subject company/ies or third party in connection with the Report of the subject company/ies during the past twelve months / has not served as an officer, director or employee of subject Company/ies and is not engaged in market making activity of the subject Company/ies.

Dealmoney group companies provides finance related product services like distribution of financial products and as such is a provider of many services like loans, mutual funds, tax & trust planning etc. mentioned in this brochure. And hence, Dealmoney do not warranty / guarantee about performance of any products and customer servicing w.r.t third party products per se.

Third party products are subject to code of conduct to be adhered to by the representatives of Dealmoney and Dealmoney is not responsible for the losses, whether actual or notional incurred by any investor. Services assured and expected may vary from actual service and Dealmoney does not guarantee about the quality of services. Investments in securities and commodities are subject to market and other risks and there is no assurance or guarantee that the objectives of any of the Investments/Schemes/product would be achieved. Past performances are only indicative and returns are not assured and guaranteed by Dealmoney group companies. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

Reports on technical and derivative analysis are based on studying charts of a stock's price movement, outstanding positions and trading volume as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. The opinions expressed in the Report are our current opinions as of the date of this report and may be subject to change from time to time without notice. Dealmoney or any persons connected with it do not accept any liability arising from use of this material/document/Report.

Information/ opinion conveyed through this material/document/Report are strictly meant for the registered Clients of Dealmoney group of Companies of the respective segments. This information is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Dealmoney or its affiliates to any registration requirement within such jurisdiction or country. This information does not constitute an offer to sell or a solicitation of an offer to buy any financial products to any person in any jurisdiction where it is unlawful to make such an offer or solicitation. No part of this material may be duplicated in whole or in part in any form and / or redistributed without the prior written consent of Dealmoney. This material/document/Report is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on directly or indirectly.

Recipients of the Report shall always independently verify reliability and suitability of the Report and opinions before investing. For Company details, please visit our website www.dealmoneyonline.com
For research related query, write to us at research@dealmoney.in